News & Updates
Filter by Specialty:
GLP-1RAs outperform DPP-4is in preventing hyperkalemia, RASi therapy discontinuation
Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.
GLP-1RAs outperform DPP-4is in preventing hyperkalemia, RASi therapy discontinuation
20 Aug 2024
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
20 Aug 2024
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.